Discovery Laboratories, Inc. (NASDAQ:DSCO)

CAPS Rating: 3 out of 5

A biotechnology company, which develops its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory disorders and diseases.

Results 1 - 20 of 67 : 1 2 3 4 Next »

Recs

0
Member Avatar dividendum (< 20) Submitted: 3/14/2014 12:25:48 PM : Outperform Start Price: $2.24 DSCO Score: -27.88

The biotechnology field is on the rise. Big things are to come.

Recs

1
Member Avatar grahamfordummies (74.16) Submitted: 12/30/2013 3:54:45 PM : Outperform Start Price: $2.26 DSCO Score: -29.27

Valuation already anticipates slow launch for Surfaxin (infant respiratory distress syndrome or RDS), but is missing the game changer development of Aerosurf (aerosolized inhalation, also for infant RDS, but avoids the intubation required for Surfaxin and all competition). Recent financing extends cash runwat through Surfaxin launch and aerosurf 2b studies in mid 15. Attractive target.

Recs

1
Member Avatar toegar2000 (48.77) Submitted: 3/2/2013 10:26:16 AM : Outperform Start Price: $2.43 DSCO Score: -57.81

Looks good

Recs

2
Member Avatar Momentum21 (95.94) Submitted: 3/16/2012 3:12:09 PM : Outperform Start Price: $2.81 DSCO Score: -78.72

Felt it was a good time to close and re-open. Started adding back shares at 2.85 now that the dilution has arrived. This doesn't have the same speculative potential at these levels but I also don't feel that the risk is what it once was...they do have a product to sell now and other products in the pipeline to push along as well...

Climb on my little DSCO...Climb on!

Recs

2
Member Avatar outoffocus (22.82) Submitted: 3/10/2012 12:45:44 PM : Outperform Start Price: $3.65 DSCO Score: -96.19

Biotech watchlist

Recs

2
Member Avatar Sbo2beme (40.35) Submitted: 3/6/2012 5:26:01 PM : Outperform Start Price: $5.24 DSCO Score: -113.83

I think JNJ will buy this stock

Recs

0
Member Avatar reachmygoals1 (< 20) Submitted: 3/3/2012 7:39:37 PM : Outperform Start Price: $2.41 DSCO Score: -77.17

likely fda approval, plenty of time for the company to get the manufacturing issue out of the way.

Recs

1
Member Avatar schuured (97.16) Submitted: 12/6/2011 10:57:14 AM : Outperform Start Price: $2.15 DSCO Score: -66.09

Completely speculative.

Recs

3
Member Avatar californiasun (54.11) Submitted: 8/24/2011 12:18:10 PM : Underperform Start Price: $1.99 DSCO Score: +81.79

History always seems to repeats itself...

Recs

2
Member Avatar calisurfer19 (48.51) Submitted: 6/29/2011 7:30:55 AM : Outperform Start Price: $2.17 DSCO Score: -70.77

Riding out the storm till patent is approved or not.

Recs

0
Member Avatar bearsniper (< 20) Submitted: 4/29/2011 2:17:06 PM : Outperform Start Price: $2.00 DSCO Score: -56.71

Should go higher now that Porte has capitulated! Seems that small biotech has taken the interest of the big boys with recent increases in price and volume.

Recs

2
Member Avatar D0min0 (64.99) Submitted: 4/5/2011 10:43:03 AM : Outperform Start Price: $1.49 DSCO Score: -44.01

FDA approval of its major drug Surfaxin will push share price to at least 10.

Recs

0
Member Avatar rangarajud (48.50) Submitted: 4/2/2011 10:11:29 AM : Outperform Start Price: $1.88 DSCO Score: -54.25

DSCO has comeout with a positive outlook during the last couple of weeks. The trend looks to be positive since they have currently completed batch 1 of trials and are waiting to complete the remaining 3 batches which will be sufficient enough to fulfill the needs of the FDA. The outlook looks promising enough with the financials too since they have a positive cash flow and are ready to submit to the FDA in early third quarter. With all this components which adds up to a successful progression towards the completion of FDA needs and requirements. My Target will be $10 to $12 before the early fouth quarter and then rise upto to $25 to $35 after the approval. ( which will still be about a $1.7 to $2 before the reverse split. )

Recs

4
Member Avatar chimpcontest (< 20) Submitted: 2/21/2011 1:27:25 PM : Outperform Start Price: $2.18 DSCO Score: -67.78

Momentum21 haiku

Disco is not dead

The FDA has it wrong

Rise up from the ash

Recs

0
Member Avatar altutone (< 20) Submitted: 2/20/2011 1:26:33 AM : Outperform Start Price: $2.18 DSCO Score: -67.78

close to " yl" price this is a bargain price and undervalued.

Recs

0
Member Avatar caradeporra (41.68) Submitted: 2/17/2011 3:37:48 PM : Outperform Start Price: $2.19 DSCO Score: -66.76

This is a swing for the fences. Hope it goes up as they get closer to FDA decision. Do you hang on for the ride up or down after the decision comes? Only buy with money you can spare because this one could go either way.

Recs

0
Member Avatar BuildingWings (< 20) Submitted: 2/17/2011 3:24:01 PM : Outperform Start Price: $2.19 DSCO Score: -66.77

Here we go....adding some to my real money portfolio.

Recs

0
Member Avatar t0bes (< 20) Submitted: 2/16/2011 11:55:55 AM : Outperform Start Price: $2.15 DSCO Score: -65.93

bouncing along

Recs

5
Member Avatar AllStarPortfolio (27.71) Submitted: 1/13/2011 3:15:07 PM : Outperform Start Price: $3.42 DSCO Score: -103.39

On December 31, 2010 at 5:49 AM, portefeuille (99.94) wrote:

Please make an "outperform" call on DSCOD (no limit). The DSCOD "pitch". This is part of a post by zzlangerhans.

-----------
"Most biotechs with a market cap under 50M are dubious or outright scam outfits with highly speculative pipelines or drug candidates that have failed late stage trials. However, there seems to be little argument regarding the efficacy or utility of Discovery's liquid surfactant Surfaxin. What has taken the share price deep into all-time lows is the repeated failure of the company to get Surfaxin approved by the FDA over the last five years. Time and again the share price has risen only to be slapped down after the FDA issued Complete Response after Complete Response, citing complicated issues related to manufacturing and controls. Meanwhile, the rest of the pipeline has struggled and the company has diluted again and again to balloon the share count to 200 million. In short, the stock deserves to be ailing. But the company unquestionably has the cash to submit Surfaxin for approval once again in Q1 2011 and await yet another FDA response, likely in Q3. Despite the exhaustion and capitulation that has brought the share price so low, there is a high likelihood that the share price will rise dramatically as investors start to wonder if maybe, just maybe, the company got it right this time."

Recs

0
Member Avatar keyscycler (< 20) Submitted: 1/2/2011 5:13:44 PM : Outperform Start Price: $3.43 DSCO Score: -104.57

Surfraxin will be approved and its day in the sun is coming

Results 1 - 20 of 67 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement